Register through Sept. 17 to receive the lowest rates for Advancing Gene + Cell Therapies for Cancer.
Learn about new approvals and the state of the field for each quarter of 2024.
The field earned the approval of three new therapies—a CAR-T therapy for myeloma in China, an AAV gene therapy for hemophilia B in Canada, and an autologous cell therapy for melanoma in the United States.
In Q2, two new RNA therapies were approved in the US; Rytelo was approved for myelodysplastic syndrome and mRESVIA, an mRNA vaccine, was approved for respiratory syncytial virus (RSV) prophylaxis.
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico